AAAAAA
Results: 1-25/42
Authors:
SHULMAN SR
LASAGNA L
Citation: Sr. Shulman et L. Lasagna, DYNAMICS OF THE INTERNATIONAL PHARMACEUTICAL MARKETPLACE - MAJOR FORCES IN THE LATE 1990S - PROCEEDINGS OF A SYMPOSIUM HELD AT TUFTS-UNIVERSITY-EUROPEAN-CENTER, TALLOIRES, FRANCE, 24-25 JULY 1997 - FOREWORD, PharmacoEconomics, 14, 1998, pp. 7-9
Authors:
LASAGNA L
Citation: L. Lasagna, DEFINING OUR FUTURE WORK, PharmacoEconomics, 14, 1998, pp. 143-146
Authors:
BYRD DM
ALLEN DO
BEAMER RL
BESCH HR
BYLUND DB
DOULL J
FLEMING WW
FRIES A
GUENGERICH FP
HORNBROOK R
LASAGNA L
LUM BKB
MICHAELIS EK
MORGAN ET
POLAND A
ROZMAN KK
SMITH JB
SWANSON HI
WADDELL W
WILSON JD
Citation: Dm. Byrd et al., THE DOSE-RESPONSE MODEL FOR DIOXIN, Risk analysis, 18(1), 1998, pp. 1-2
Authors:
MELTZER HY
CASEY DE
GARVER DL
LASAGNA L
MARDER SR
MASAND PS
MILLER D
PICKAR D
TANDON R
Citation: Hy. Meltzer et al., CLINICAL DEVELOPMENT OF ATYPICAL ANTIPSYCHOTICS - RESEARCH DESIGN ANDEVALUATION, The Journal of clinical psychiatry, 59, 1998, pp. 10-16
Authors:
MELTZER HY
CASEY DE
GARVER DL
LASAGNA L
MARDER SR
MASAND PS
MILLER D
PICKAR D
TANDON R
Citation: Hy. Meltzer et al., ADVERSE-EFFECTS OF THE ATYPICAL ANTIPSYCHOTICS, The Journal of clinical psychiatry, 59, 1998, pp. 17-22
Authors:
MELTZER HY
CASEY DE
GARVER DL
LASAGNA L
MARDER SR
MASAND PS
MILLER D
PICKAR D
TANDON R
Citation: Hy. Meltzer et al., EVALUATING THE EFFECTS OF ANTIPSYCHOTICS ON COGNITION IN SCHIZOPHRENIA, The Journal of clinical psychiatry, 59, 1998, pp. 35-40
Authors:
MELTZER HY
CASEY DE
GARVER DL
LASAGNA L
MARDER SR
MASAND PS
MILLER D
PICKAR D
TANDON R
Citation: Hy. Meltzer et al., ATYPICAL ANTIPSYCHOTICS FOR TREATMENT OF DEPRESSION IN SCHIZOPHRENIA AND AFFECTIVE-DISORDERS, The Journal of clinical psychiatry, 59, 1998, pp. 41-45
Authors:
MELTZER HY
CASEY DE
GARVER DL
LASAGNA L
MARDER SR
MASAND PS
MILLER D
PICKAR D
TANDON R
Citation: Hy. Meltzer et al., TREATMENT OF SPECIAL POPULATIONS WITH THE ATYPICAL ANTIPSYCHOTICS, The Journal of clinical psychiatry, 59, 1998, pp. 46-52
Authors:
LASAGNA L
Citation: L. Lasagna, PRESENTATION OF THE AIR-OF-PHARMACOLOGY-AND-EXPERIMENTAL-THERAPEUTICS, TUFTS-UNIVERSITY SCHOOL-OF-MEDICINE, Journal of clinical pharmacology, 38(7), 1998, pp. 570-571
Authors:
LASAGNA L
Citation: L. Lasagna, EVENING REFLECTIONS, Journal of clinical pharmacology, 38(7), 1998, pp. 575-576
Authors:
LASAGNA L
KAITIN KI
Citation: L. Lasagna et Ki. Kaitin, ISSUES FACING THE NEW FDA COMMISSIONER, Science, 282(5392), 1998, pp. 1263-1263
Authors:
LASAGNA L
Citation: L. Lasagna, MARIJUANA, THE FORBIDDEN MEDICINE - REVISED AND EXPANDED EDITION - GRINSPOON,L, BAKALAR,JB, The Journal of nervous and mental disease, 186(3), 1998, pp. 195-195
Authors:
DIMASI JA
HEALY EM
LASAGNA L
Citation: Ja. Dimasi et al., TRENDS IN THE INTRODUCTION OF NEW DRUGS BY PHARMACEUTICAL FIRMS, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 34-34
Authors:
MANOCCHIA M
LASAGNA L
Citation: M. Manocchia et L. Lasagna, ISSUES IN PHARMACEUTICAL LOTTERIES - THE CASE OF INTERFERON BETA-1B, Clinical pharmacology and therapeutics, 62(3), 1997, pp. 241-247
CLINICAL RELEVANCE OF POSTURAL STABILITY MEASURES TO AN ASSESSMENT OFRISK OF FALLING IN MOST ELDERLY
Authors:
LASAGNA L
BALOH RW
BERG K
MAKI B
NEVITT M
WOLFSON L
ALLARD S
Citation: L. Lasagna et al., CLINICAL RELEVANCE OF POSTURAL STABILITY MEASURES TO AN ASSESSMENT OFRISK OF FALLING IN MOST ELDERLY, Journal of the American Geriatrics Society, 45(9), 1997, pp. 176-176
Authors:
LASAGNA L
Citation: L. Lasagna, COST-CONTAINMENT, HEALTH-CARE REFORM AND PHARMACEUTICAL INNOVATION - TAKING STOCK IN 1995 - PROCEEDINGS OF A SYMPOSIUM HELD AT TUFTS-UNIVERSITY-EUROPEAN-CENTER, TALLOIRES, FRANCE, JULY 20-21, 1995 - INTRODUCTION, PharmacoEconomics, 10, 1996, pp. 1-3
Authors:
SHULMAN SR
LASAGNA L
Citation: Sr. Shulman et L. Lasagna, COST-CONTAINMENT, HEALTH-CARE REFORM AND PHARMACEUTICAL INNOVATION - TAKING STOCK IN 1995 - PROCEEDINGS OF A SYMPOSIUM HELD AT TUFTS-UNIVERSITY-EUROPEAN-CENTER, TALLOIRES, FRANCE, JULY 20-21, 1995 - FOREWORD, PharmacoEconomics, 10, 1996, pp. 7-9
Authors:
LASAGNA L
Citation: L. Lasagna, DEFINING OUR FUTURE WORK, PharmacoEconomics, 10, 1996, pp. 139-141
Authors:
LASAGNA L
FREI E
Citation: L. Lasagna et E. Frei, THE IMPACT OF REGULATIONS, TRADITION, AND EXPERIMENTAL-DESIGN ON CLINICAL CANCER TRIALS - REPORT AND RECOMMENDATIONS RESULTING FROM WASHINGTON CANCER TRIALS CONFERENCE, American journal of clinical oncology, 19(4), 1996, pp. 325-329
Authors:
LASAGNA L
Citation: L. Lasagna, OVER-THE-COUNTER HYPNOTICS AND CHRONIC INSOMNIA IN THE ELDERLY - UPDATE, Journal of clinical psychopharmacology, 16(2), 1996, pp. 191-191
Authors:
DIMASI JA
MANOCCHIA M
LASAGNA L
Citation: Ja. Dimasi et al., INITIATIVES TO SPEED NEW DRUG DEVELOPMENT AND REGULATORY REVIEW - THEIMPACT OF FDA-SPONSOR CONFERENCES, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 13-13
Authors:
KAITIN KI
MANOCCHIA M
LASAGNA L
Citation: Ki. Kaitin et al., THE NEW DRUG APPROVALS OF 1993, 1994, AND 1995 - TRENDS IN DRUG DEVELOPMENT, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 16-16
Authors:
DIMASI JA
HANSEN RW
GRABOWSKI HG
LASAGNA L
Citation: Ja. Dimasi et al., RESEARCH-AND-DEVELOPMENT COSTS FOR NEW DRUGS BY THERAPEUTIC CATEGORY - A STUDY OF THE UNITED-STATES PHARMACEUTICAL-INDUSTRY, PharmacoEconomics, 7(2), 1995, pp. 152-169
Authors:
LASAGNA L
Citation: L. Lasagna, OVER-THE-COUNTER HYPNOTICS AND CHRONIC INSOMNIA IN THE ELDERLY, Journal of clinical psychopharmacology, 15(6), 1995, pp. 383-386
Authors:
LASAGNA L
Citation: L. Lasagna, THE HELSINKI DECLARATION - TIMELESS GUIDE OR IRRELEVANT ANACHRONISM, Journal of clinical psychopharmacology, 15(2), 1995, pp. 96-98